Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • Warm AIHA
      • COVID-19
      • IRAK1/4
      • RIPK1
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Grifols
      • Kissei
      • Lilly
      • Medison
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Jul 12, 2007 7:30am EDT

Rigel Announces Start of Phase 1 Combination Therapy Study of R763/AS703569 in Advanced Malignancies

Jun 21, 2007 7:30am EDT

Rigel to Present at Jefferies Healthcare Conference

Jun 07, 2007 7:30am EDT

Rigel to Present at Needham Biotechnology Conference

May 17, 2007 7:30am EDT

Rigel to Present at JMP Securities Research Conference

May 02, 2007 9:50pm EDT

Rigel Announces Pricing of Public Offering of Common Stock

Apr 30, 2007 6:00am EDT

Rigel Announces Offering of 5,000,000 Shares of Common Stock

Apr 16, 2007 7:30am EDT

Rigel to Present New Research Programs at AACR Meeting

Apr 11, 2007 7:30am EDT

Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma

Mar 14, 2007 7:30am EDT

Rigel Announces Presentation at the Lehman Brothers Global Healthcare Conference

Feb 13, 2007 7:30am EST

Rigel Announces Initiation of Phase 1 Study Evaluating R763 in Hematological Malignancies

  • Previous
  • 1…
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2022 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin